GLP-1 maintenance phase: what the science says about keeping weight off

What's this video probably claiming?

Based on the caption and hashtags, @michellesays appears to be documenting her experience transitioning from active weight loss on a GLP-1 medication to a maintenance phase, likely at a reduced dose or after stopping. The "glp1reset" hashtag is particularly telling, suggesting she may be cycling her medication, taking breaks, or attempting to sustain results through behavioral habits rather than pharmacology alone. She's framing maintenance as potentially harder than the loss phase itself, which is actually one of the more honest things you'll hear on GLP-1 TikTok. The PCOS hashtag adds relevant context: women with polycystic ovary syndrome often have compounding metabolic challenges, including insulin resistance and hormonal disruptions, that make weight maintenance genuinely more difficult than it is for the general population. The overall message seems to be about sustainable habits over quick fixes, which is directionally sound, but the devil is in the specifics.

What does the science actually show?

Weight regain after stopping GLP-1 medications is not a social media myth. It is well-documented. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who discontinued semaglutide 2.4mg after 20 weeks regained approximately two-thirds of their lost weight within 12 months. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed similar regain patterns after tirzepatide discontinuation. The biological explanation matters here: GLP-1 receptor agonists work partly by suppressing appetite through central nervous system pathways, and when the drug is removed, those appetite signals return. This is not a willpower failure. It is a physiological rebound. For women with PCOS specifically, a 2022 review in Frontiers in Endocrinology noted that insulin resistance and elevated androgens create a metabolic environment that actively resists fat loss maintenance, making behavioral interventions alone less effective than in metabolically typical individuals.

Where does the social media noise diverge from clinical reality?

The "GLP-1 reset" framing circulating on TikTok deserves scrutiny. It implies that periodic breaks from medication are intentional, strategic, and beneficial. There is currently no peer-reviewed evidence supporting planned GLP-1 cycling as a superior maintenance strategy. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) demonstrated that continuous semaglutide use over 104 weeks produced sustained weight loss, while discontinuation consistently produced regain. The idea that habits built during the loss phase can independently sustain results is appealing but overstated for most patients. Behavioral interventions without pharmacological support show modest maintenance outcomes, averaging 2-4 kg of sustained loss beyond placebo in long-term trials (Wadden et al., 2020, Obesity). The framing of "listening to your body" is not inherently wrong, but the body's hunger signals post-GLP-1 are often dysregulated in ways that make intuitive eating genuinely unreliable as a standalone strategy for this population.

What should you actually know?

If you are on a GLP-1 medication and thinking about the maintenance phase, the clinical picture is more complex than most TikTok content acknowledges. Obesity is classified as a chronic disease by the American Medical Association, and GLP-1 medications are increasingly being considered long-term treatments rather than finite courses. That said, not everyone needs to stay on the highest dose indefinitely. Some patients do maintain on lower doses, though dose reduction strategies require individualized medical supervision. For PCOS patients specifically, the metabolic benefits of GLP-1 medications extend beyond weight, including improvements in androgen levels and insulin sensitivity, which makes an abrupt stop particularly worth discussing with a provider. The honest take here is that @michellesays is touching on something real: maintenance is hard, and the social media version of GLP-1 journeys often skips this part entirely. Just make sure any "reset" strategy is built with a clinician, not a comment section.